Every 8-K that Ainos Inc (AIMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AIMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMD filings page.
Ainos, Inc. reported second-quarter 2026 results, highlighting ongoing commercialization of its AI Nose Smell AI platform while remaining deeply loss-making. Revenue for the quarter ended June 30, 2026 was $152, down from $4,663 a year earlier; six-month revenue was $313 versus $110,870 in 2025.
The company recorded a Q2 2026 net loss of $(4,594,731) compared with $(4,084,990) in Q2 2025, and a six-month net loss of $(7,054,531) versus $(7,371,012). Basic and diluted net loss per share was $(0.62) for the quarter and $(1.05) year-to-date. Cash and cash equivalents increased to $1,422,912 at June 30, 2026 from $417,353 at December 31, 2025.
Balance sheet leverage rose, with current liabilities of $16,277,500 including $11,000,000 of current convertible notes and a $2,812,940 loan payable. Total stockholders’ equity declined to $3,283,985, driven by an accumulated deficit of $(74,574,859). Management emphasized expanding AI Nose deployments, an initial $2.1 million backend semiconductor arrangement, and datasets totaling approximately 613 million industrial smell records to support its Smell AI platform.
Ainos, Inc., a Texas-based company listed on Nasdaq under AIMD and AIMDW, changed its independent registered public accounting firm. On July 9, 2026, the company dismissed YCM CPA INC. following expiration of its engagement and, on the same day, the audit committee engaged DLEE Accountancy, Inc. as the new independent registered public accounting firm.
The company states it had no disagreements with YCM on accounting principles, financial statement disclosure, or auditing scope or procedures, and reports no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S‑K. Ainos indicates it did not consult DLEE on potential audit opinions or accounting issues before the engagement. YCM has been asked to provide a letter to the SEC regarding its agreement with these statements.
Ainos, Inc. entered into a General Agreement for Omnibus Credit Lines with CTBC Bank Co., Ltd., providing a short-term unsecured credit facility of NT$62,000,000 (approximately US$1,937,800). Outstanding borrowings bear interest at 2.5% per annum. The facility has a three-month term and matures on September 30, 2026. It is unsecured and includes customary events of default, giving Ainos additional near-term funding flexibility.
Ainos, Inc. reported first quarter 2026 results showing minimal revenue and a narrower loss as it advances its AI Nose commercialization strategy. Revenue for the quarter was $161, compared with $106,207 a year earlier, reflecting the shift toward infrastructure-focused AI Nose deployments still in early stages.
The company reported a net loss of $2.46 million, improving from a $3.29 million loss in the prior-year quarter, as operating expenses declined about 30% year-over-year to approximately $2.28 million. Cash and cash equivalents rose to $2.84 million from $0.42 million, supported by a previously announced NT$90 million (approximately $2.8 million) financing, while total liabilities increased to $16.39 million and stockholders’ equity decreased to $5.69 million.
Operationally, Ainos continued deploying AI Nose under a roughly three-year $2.1 million commercial arrangement in backend semiconductor manufacturing, initiated pilots in front-end semiconductor environments, expanded healthcare infrastructure pilots, and further developed its Smell ID datasets and Smell Language Model to support long-term Smell AI platform commercialization.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.
Ainos, Inc. reported that on December 30, 2025 it entered into a distribution agreement with Trusval Technology Co. Ltd. covering its AINOS AI Nose and related products and services. The agreement runs for three years and provides Trusval with one-year exclusive distribution rights for Products sold to certain clients, after which exclusivity may change according to the contract terms. This arrangement is intended to govern how Ainos’ AI Nose offerings reach designated customers through Trusval as a distributor.
Ainos, Inc. (AIMD) filed an 8-K detailing shareholder voting results and the furnishing of a press release with results for the quarter ended September 30, 2025.
At the November 7 Annual Meeting, a quorum was present with 3,226,793 votes, representing approximately 67.63% of outstanding votes. Seven directors were elected with vote support near or above 98%. Shareholders approved the ratification of YCM CPA INC. as independent auditor for the fiscal year ending December 31, 2025.
Shareholders also approved the reservation of up to 950,000 shares of common stock as special stock awards not issued under the 2023 Stock Incentive Plan. As of the September 17 record date, 4,771,184 common shares were outstanding and entitled to vote. The company furnished, but did not file, a press release announcing quarterly results as Exhibit 99.1.
Ainos, Inc. entered a Fourth Addendum to its Product Development Agreement with Taiwan Carbon Nano Technology Corporation (TCNT). The amendment sets a fee for the exclusive use of patents of $50,000 per month plus 5% sales tax for a two-year period starting October 16, 2025, replacing the prior one-year period starting October 16, 2024.
TCNT controls the company through its majority interest in Ainos KY and direct ownership, with Ainos KY holding majority voting power via voting agreements. The parties may negotiate payment terms and subsequent licensing methods after the two-year period. An English translation of the Fourth Addendum is filed as Exhibit 10.1.